Mazdutide vs Orforglipron

Mazdutide and Orforglipron represent divergent approaches to targeting the GLP-1 pathway for metabolic research. Mazdutide is a once-weekly injectable peptide that co-agonizes GLP-1 and glucagon receptors, offering a dual mechanism to address appetite suppression and energy expenditure. Orforglipron, in contrast, is a non-peptide oral small molecule that selectively activates the GLP-1 receptor with once-daily dosing. While both are investigated for weight management and glycemic control, their structural differences, route of administration, and receptor selectivity create distinct research contexts. This comparison highlights key tradeoffs in mechanism, evidence strength, and practical considerations for researchers evaluating these compounds.

Mazdutide (IBI362) is a synthetic peptide dual agonist of GLP-1 and glucagon receptors, with a molecular weight of approximately 4233.7 g/mol. Developed by Innovent Biologics in collaboration with Eli Lilly, it is administered as a once-weekly subcutaneous injection. The dual agonism is designed to combine GLP-1-mediated appetite suppression and glucose-dependent insulin secretion with glucagon-mediated increases in energy expenditure and hepatic fat oxidation. In June 2024, Mazdutide received regulatory approval in China for chronic weight management in adults with obesity, marking the first global approval for a dual GLP-1/glucagon agonist. Phase III trials in China are ongoing for type 2 diabetes. Published research in Chinese cohorts reports significant weight loss, improved glycemic control, and reductions in hepatic fat content, with effects that appear additive compared to selective GLP-1 agonists.

Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. It is structurally distinct from peptide-based GLP-1 agonists, offering oral bioavailability and once-daily dosing without food restrictions. The compound is currently in Phase III development under the ATTAIN trial program for type 2 diabetes and obesity. Phase II results demonstrated weight loss approaching that of injectable GLP-1 agonists, with mean reductions of up to 14.7% body weight at 36 weeks in some dose groups. Glycemic control in type 2 diabetes patients was also significant, with HbA1c reductions comparable to injectable comparators. Orforglipron's oral formulation and lack of food restrictions provide a practical advantage over oral semaglutide, though it is not a peptide and thus falls outside the peptide class for research categorization.

Both Mazdutide and Orforglipron are investigated for weight management and metabolic health, including obesity and type 2 diabetes. Mazdutide's dual agonism extends its research scope to hepatic steatosis and energy expenditure, while Orforglipron's oral route offers convenience in adherence studies. No additional unique applications beyond these metabolic endpoints are reported for either compound in the current literature. Researchers should consider that Mazdutide provides a peptide-based dual mechanism with injectable delivery, whereas Orforglipron offers an oral small-molecule alternative with a narrower receptor target. The choice between them depends on whether the study aims to explore dual receptor pharmacology or oral GLP-1 monotherapy.

Mazdutide's safety profile is consistent with GLP-1 receptor agonist class effects, including dose-dependent gastrointestinal adverse events such as nausea, vomiting, and diarrhea. These are generally transient and most common during dose titration. A mild increase in heart rate has been observed, aligning with GLP-1 agonist class effects. Orforglipron also exhibits GI adverse events, with nausea reported in 30–40% of participants, vomiting in 14–22%, and diarrhea in 16–22% across Phase II trials. Constipation was also noted. Discontinuation rates due to GI events ranged from approximately 10–17%, lower than those seen with the BID oral GLP-1 agonist danuglipron. Both compounds show dose-dependent GI tolerability, but Orforglipron's oral administration may introduce additional variables such as gastrointestinal absorption and food interactions, though current data suggest no food restrictions are needed.